Obi 3424
T-Cell Acute Lymphoblastic Leukemia
Explore 76 assets in T-Cell Acute Lymphoblastic Leukemia →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
SWOG Cancer Research Network
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04315324CT.gov Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T-Cell Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Obi 3424 (this asset) | SWOG Cancer Research Network | P1/2 | CCC · 48 |
| Vincristine Sulfate | Children's Oncology Group | P3 | BB |
| Crisantaspase | University of Washington | P3 | BB |
| Mercaptopurine Anhydrous | SWOG Cancer Research Network | P3 | BB |
| Pegaspargase | Children's Oncology Group | P3 | BB |
| Daunomycin | SWOG Cancer Research Network | P3 | BB |
| Prednisone | Children's Oncology Group | P3 | BB |
| Adriamycin | SWOG Cancer Research Network | P3 | BB |
| Cytarabine | SWOG Cancer Research Network | P3 | BB |
+42 more in the T-Cell Acute Lymphoblastic Leukemia cohort
Other indications for Obi 3424
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | P2 | B · 58 |
| T-Lymphoblastic Lymphoma | — | P1/2 | CCC · 48 |
| Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Obi 3424 in T-Cell Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/obi-3424-t-cell-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →